David P. Perry is President at Anacor Pharmaceuticals, Inc. (ANAC). They have made 1 open-market trade across 1 company since 2013, most recently 2024-02-09.
CIK 0001105941
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $1.8M since 2023, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BTTX | BUY | 2023-07-27 | 2023-07-31 | $0.73 | $1.8M | -7.8% | -19.7% | -79.8% |
| ANAC | SELL · 10b5-1 | 2014-03-04 | 2014-03-06 | $20.22 | $1.3M | -19.4% | +2.3% | +2.3% |
| ANAC | SELL · 10b5-1 | 2014-02-04 | 2014-02-05 | $17.00 | $255K | -19.4% | +2.3% | +2.3% |
| ANAC | SELL · 10b5-1 | 2014-01-08 | 2014-01-09 | $16.32 | $1.1M | -19.4% | +2.3% | +2.3% |
| ANAC | SELL · 10b5-1 | 2013-12-05 | 2013-12-09 | $16.23 | $655K | -19.4% | +2.3% | +2.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.